Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As previously disclosed, on January 30, 2013, Amarantus Bioscience Holdings, Inc. (the “Company”) executed an amendment to a Convertible Promissory Note payable to Dominion Capital, LLC (“Dominion”) or its registered assigns (the “Dominion Note”), dated November 14, 2012, providing for an increase in the purchase price for such note from $600,000 to $2,000,000, to be disbursed in tranches through April 26, 2013. The Dominion Note is convertible into shares of the Company’s common stock, subject to certain restrictions, at a price of $0.10 per share. On April 12, 2013, the Company received the final $200,000 tranche from Dominion, such that the Company has received an aggregate of $2,000,000 in gross proceeds in accordance with the terms of the Dominion Note.
497K prospect LEGG MASON financial firm thinks Pinnacle is a deal at these levels!
She's coming out of CH11
Folks, CUSIP is not intended to fry shorts. AMBS is moving to the AMEX with a name change. That will enable prono bono marketing Systems which the OTC does not have.
Thanks Muga! AMBS is a loading zone for next week.
AMBS in loading zone next week CC huge!. Found AMBS GOOGLE DOC on diagnostics. https://docs.google.com/a/students.towson.edu/document/d/1ihv24O8iUYILQocEtGTicKO7UJtaMQiUmUr_5hEbFL0/edit
FOLKS ANOTHER 400K ON BID GROUPS ARE LOADING FOR NEXT WEEK.
200k back on bid folks demand is huge!
Morning Shake day traders are ready for a bounce
REAL AMBS INFO: Factual DD With Supporting Evidence
The company has significant value.
The company is run by a father-son duo. Dr. John Commissioning was an officer of the National Institute of Health neurotrophic division before starting Amarantus. Gerald has a business degree from Stanford and ties to the football community (TBI). Together, their salaries are less than 100k... CHECK FORBES!
The research company outsources its lab work to avoid unnecessary overhead and debt.
MANF is very valuable and has DOZENS of academic articles backing recent findings.
The company has a $5.8 billion dollar market potential, with $800 million expected revenue in the medium-term future.
The stock is up 2,000% and many are HAPPY with huge gains.
AMBS has the potential to be one of the BEST PENNY STOCK OF OUR GENERATION.
The website is full of factual information, SEC filings, and insight for investors to use in due diligence.
Know what you own!
https://docs.google.com/a/students.towson.edu/document/d/1ihv24O8iUYILQocEtGTicKO7UJtaMQiUmUr_5hEbFL0/edit
https://docs.google.com/document/d/1V10erwVdBvy6Um35Ay8XV0wV3TAPr6oME2fJG_jFvl4/edit
Anyone remember the old days? Shake in AM, then a nice bounce? CC speculation will drive PPS green.
80grand is still on bid.
After loading zone huge bounce.
Loading zone! 1million shares on bid
Another loading zone in the low .08s
Institutions are buying..MM- MURF About Murphy & Durieu
Murphy & Durieu is one of Wall Street’s oldest financial services and inter-dealer brokerage firms. Founded in 1929, the firm began as a Fixed Income Odd-Lot Trader and became a Member of The New York Stock Exchange in 1974, where it has been a member for over 35 years. Today Murphy & Durieu is a full service investment and inter-dealer brokerage active in the global fixed income, derivative and equity markets, acting as a principal or an agent to facilitate execution of transactions between investment banks and broker-dealers throughout the world. Our Global Capital Markets division provides our clients with unparalleled distribution and global trade execution; we are a full service Market Making Desk and members of all relevant exchanges including the New York Stock Exchange. Murphy & Durieu’s Investment Banking division offers unique Corporate Finance solutions in Equity and Debt, Mergers & Acquisitions, and Structured Finance. Murphy’s Domestic Research group provides high quality, actionable research. Our fundamental analysts have knowledge and expertise in Health Care including, Health Care Service and Health Care Equipment (Med Tech)
Specialties
Equity Research - Healthcare- Med Tech, Healthcare Services
Headquarters
120 Broadway 17th Floor New York, New York 10271 United States
Website
http://www.murphy.com
Industry
Financial Services
Type
Public Company
Company Size
201-500 employees
Welcome D*hade, enjoyed your presence from early Fall.
The street is loading AMBS and their editors say they're not. AMBS is getting more attention than this website. Fun has not even started.
Adam Feuerstein is loading. Mark my words. His trading group is two faced. Bad calls are profits to him. "You cannot win them all".
FIB EXTENSION hit 61.8%, then 100% from prior run. Look for small consolidation, then going to .1
Tearing through .085 wall.
Day traders sold this morning, and now are forced to buy-in.
AMBS running
Thanks LewS. QUOTE
My theory is that the O/S was raised as part of a JV or partnership with the swiss firm, most likely Roche according to our esteemed Dr. Jerry. If all the new shares were given to them they would have a significant stake in the company.
Read this email from Gerald:
Quote:Hi Lewis,
Actually not too much from other shareholders thus far. As far as the
increase, everything that we have stated is correct. We haven't
entered into financing agreements since the last Q. What has happened
specifically regarding the increase in O/S will be disclosed in our
10K filing, which will be filed in the near future *April 15* as we finalize a
number of things that are meant to build value in the near-term.
While the dilution was indeed significant, what it bought the
shareholders was a much stronger company with much better prospects
for future growth, additional product lines in our diagnostics
platform and an entity that people with high repute and who are
recognized in the field are happy to be associated with. I think the
future is extremely bright from here, and agree entirely with you that
we are substantially undervalued.
Best Regards,
Gerald
From an old PR:
Quote:The Company has retained a Swiss neuroscience-focused consulting firm to conduct a full audit of the data derived from these experiments and assist the Company in planning for its IND package. The Company will be reporting additional rodent data in the first quarter on a 6-OHDA neuroprotection rat model of Parkinson's disease where both MANF and GDNF were delivered to the substantia nigra. The final report for all rodent experiments will be made public in the second quarter following completion of the data audit.
We just found out the audit was completed. Also if you look back at an old email from smoke_em, Gerald was originally not planning any more data tests outside of academia following OneMed. So why the change of plans? Big pharma wanted to validate the data before agreeing to a partnership. It looks like the deal might have just been closed, we will see. I agree with Solantey that only a few people seem to really understand what is going on right now, its very exciting times. I'll tell you one thing, hotstocked and similar penny stock authors sure as hell don't see the big picture.
Markets run on speculation. So, that in mind MjFox grants AMBS Neurotrophic Factors Challenge 2013 Grant next week or sometime this month. https://www.michaeljfox.org/research/grant-detail.php?id=6
Keep in mind this is only one of many factors to drive PPS up
Validity test on MANF is what MJFF was waiting for. Tests are in.
Could you point me in the right direction of excellent DD?
Thanks Muga AMBS continues to gAP!!!
AMBS gaping up again
Law of Supply and Demand. AMBS huge Demand, LIMITED SUPPLY. Longs locked her up
Thanks Muga Go AMBS!
.08 bid keeps growing.
Someone needs 900k share .08
As some who sold and can't bare AMBS going up. This is called a buy-in and chase the ask. Very thin to .09
You are very wrong premarket is lighting up
Early bird gets the worm. Speculate to late and the worm will not be juicy. Gerald is moving Amarantus Holdings out of penny land very quickly. This is not a normal penny stock and those who bash damn right know it. Those who listen to others saying they will buy at a later date. Good luck at .5. Amarantus is the new kid on the block and once the street understands what the diagnostics/molecule can do look for 1.00. Guess what they have TIO Cook to do that.
Get ready Folks AMBS big news out MANF. Institutional buyers are in
AMBS big News Gaping at open